L. Whelan

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

S. Kaplan, L. Cardozo, T. Crook, 2014, International journal of clinical practice.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double‐blind, placebo‐controlled EIGHT trial

C. Chapple, F. Haab, E. Mangan, 2014, BJU international.

An International, Randomized, Double-blind, Placebo-controlled, Phase III Trial of Pregabalin Monotherapy in Treatment of Patients with Fibromyalgia

P. Arsenault, A. Winkelmann, B. Zeiher, 2011, The Journal of Rheumatology.

Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine

P. Maruff, G. Kay, B. Malhotra, 2012, Postgraduate medicine.

Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia

B. Herman, B. Zeiher, L. Pauer, 2009 .

Validation of the Daily Diary of Fatigue Symptoms—Fibromyalgia (DFS-Fibro)

T. Symonds, I. Hirsch, R. Arbuckle, 2013 .

Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry

G. Lose, A. Darekar, D. Scholfield, 2014, International Urogynecology Journal.